Introduction
============

Pulmonary arterial hypertension (PAH) is a rare vascular disorder characterised by increased pulmonary vascular resistance and right heart failure. PAH can be idiopathic (IPAH), heritable (HPAH) or associated with other conditions (APAH) as connective tissue diseases, congenital heart diseases, portal hypertension, drug or toxin exposure \[[@B1],[@B2]\]. Heterozygous germline mutations in the *bone morphogenetic protein type 2 receptor*(*BMPR2*) have been identified as a gene underlying HPAH in approximately 10 to 40% of patients with apparently sporadic disease \[[@B1],[@B3]-[@B6]\] and in 58% to 74% of patients with familial PAH \[[@B1],[@B4],[@B6],[@B7]\]. In total 298 different mutations in *BMPR2*have been identified so far in independent patients including those with a known PAH family history, sporadic disease and PAH associated with other diseases \[[@B1]\]. In a few PAH patients mutations in other genes participating in the BMPR2 signalling pathway have been identified, as *Activin A receptor type II-like 1*(*ACVRL1*, also called *ALK1*) \[[@B8]\], *Endoglin*\[[@B9]\], and *SMAD8*\[[@B10]\]. Nevertheless, there is still a small proportion of patients with familial aggregation of PAH in which no gene defects can be detected so far \[[@B7],[@B11]\].

HPAH patients carrying a *BMPR2*mutation develop the disease approximately 10 years earlier than non-carriers, with more severe hemodynamic changes \[[@B6],[@B12]-[@B15]\] and a reduced response to acute vasodilator testing \[[@B6],[@B12],[@B14]-[@B16]\]. Patients carrying *ACVRL1 or Endoglin*mutations have been characterised to be of younger age at diagnosis and death as patients without mutations \[[@B14]\]. A recent study of Austin et al \[[@B17]\] showed that HPAH female patients with missense mutations in the *BMPR2*gene had a more severe disease than patients with truncating mutations. These publications indicate that the clinical phenotype of PAH can be affected by the type of mutation. However, most data comparing clinical features between *BMPR2*mutation carriers and non-carriers have been obtained from registries as from the French Network of Pulmonary Hypertension \[[@B6],[@B13]-[@B15]\], and from centres in the United States as the New York Presbyterian Pulmonary Hypertension Center \[[@B12]\], the Utah Pulmonary Hypertension Genetics Project \[[@B16]\] or the Vanderbilt University School of Medicine, Nashville, Tennessee \[[@B7],[@B17],[@B18]\] and are retrospective in design. The genetic mechanism of PAH remains unclear in those families in which no *BMPR2*mutation can be detected.

Therefore, the aim of this study was to evaluate hemodynamic parameters and genetic status in a large German cohort of patients using a prospective design. The frequency of known *BMPR2*mutations has been analysed and a detailed search for new *BMPR2*mutations has been performed. In this study, we present 12 new *BMPR2*mutations and 3 unclassified variants which have not been described before. Furthermore, we describe the clinical features of families with confirmed familial aggregation of PAH but no detectable mutations of the *BMPR2*gene and tested these families for mutations of the genes *ACVRL1*, *Endoglin*, and *SMAD8*.

Materials and methods
=====================

Study Population
----------------

This prospective study investigated adult patients (≥ 18 years) with confirmed sporadic IPAH or familial HPAH between January 2006 and December 2009, who agreed to a genetic testing and from whom EDTA-blood was obtained. Patients have been seen in the centres of pulmonary hypertension (PH) of Heidelberg and Giessen and underwent complete clinical and genetic work-up. In all patients a right heart catheterization and a detailed family history was obtained and a three to four generation pedigree was constructed. For deceased relatives, medical records were reviewed when available and the diagnosis of PAH was based on the criteria used for index patients as well as on the results of the post mortem examination. Familial disease has been postulated when PAH was diagnosed in at least two family members. Sporadic IPAH was stated when family history and medical records of family members were negative.

The Ethics Committees of the Medical Faculties of the Universities of Heidelberg and Giessen approved the protocol of this study, and the family members gave their written informed consent. All participating patients and family members underwent genetic counselling. The study was part of the European Projects \"Pulmotension\" which belongs to the 6th European Framework.

Mutation analysis of the *BMPR2*gene
------------------------------------

EDTA-blood samples were collected for genetic analysis in all patients and from all family members, if available. Human genomic DNA was prepared from peripheral blood lymphocytes. The complete coding sequence and exon/intron boundaries of the *BMPR2*gene from each individual were amplified and analysed by DHPLC and/or direct sequencing as previously described \[[@B4]\]. HPAH patients without an obvious *BMPR2*mutation were also analysed for mutations in the *BMPR2*promoter, the *ACVRL1*gene, *Endoglin*gene, and *SMAD8*gene. In HPAH cases all first degree relatives were investigated for the mutation identified in the index patient. Primer sequences and PCR conditions are available upon request. Standard DNA sequencing reactions were performed using version 1.1 of Big Dye terminator cycle sequencing kit (Applied Biosystems Inc., Darmstadt) and were analysed on a Genetic Analyzer 3100 (Applied Biosystems Inc., Darmstadt). Pathogenicity of identified sequence alterations were assessed by use of the program MutationTaster <http://www.mutationtaster.org/> and by ESEfinder 3.0 software <http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi>.

Screening for larger rearrangements was performed with the SALSA Multiplex Ligation-dependent Probe Amplification (MLPA) P093-B1 HHT/PPH1 probe mix kit (MRC-Holland BV, Amsterdam, The Netherlands).

The mutation nomenclature refers to the NCBI human *BMPR2*nucleotide sequence (NCBI: NM_001204) and is expressed following the standard recommendations of the Association for Molecular Pathology Training and Education Committee \[[@B19]\] with the A of the ATG start codon denoted as +1 and the initiator methionine as codon 1.

Results
=======

Study Population
----------------

Between January 2006 and December 2009 in total 262 patients agreed to participate in the study and EDTA-blood has been stored for genetic analysis. Thirty-one patients had to be excluded due to several reasons. In 23 patients the further diagnostic work-up revealed a non-idiopathic form of pulmonary hypertension. In 3 patients the clinical data have been incomplete and in another 5 patients not enough blood for genetic analysis has been obtained. Thus, the study group for a complete genetic work-up consisted of 231 patients. All investigated patients were of Caucasian origin. About 91% of the analysed patients included in this study were of German ancestry, 4.8% were sent from different European countries (as Spain, Belgium, Netherlands, Sweden, Italy, and Eastern Europe), 1.3% were of Arabian ancestry and 2.6% of Turkish ancestry.

Genetic disposition to PAH in the study population
--------------------------------------------------

Of the 231 PAH index patients 22 (9.5%) revealed a confirmed familial aggregation of the disease with at least one further affected family member. The remaining 209 patients (90.5%) with negative family history have been classified as sporadic IPAH cases (Figure [1](#F1){ref-type="fig"}). In 49 patients of the 231 PAH index patients (21.2%) including 19 of the 22 familial (86.4%) and in 30 of the 209 (14.4%) apparently sporadic cases, mutations in the *BMPR2*gene have been identified (Figure [1](#F1){ref-type="fig"}).

![**Genetic disposition of the study population**. PAH = pulmonary arterial hypertension, IPAH = idiopathic PAH. The figure shows the proportion of *BMPR2*mutation carriers in the study population, female to male proportion and the mean age at diagnosis.](1465-9921-12-99-1){#F1}

Clinical and hemodynamic characteristics
----------------------------------------

The mean age at diagnosis of all 231 patients was 43.49 ± 12.75 years; 168 patients were females reflecting a female to male ratio of 2.7:1. *BMPR2*mutation carriers were significantly younger at diagnosis than non-carriers (Table [1](#T1){ref-type="table"}). In three families without any identified mutation in *BMPR2*, *ACVRL1*, *ENG*, or *SMAD8*the mean age at diagnosis (27.3 y ± 4.78) was significantly lower than that of the mutation carriers and non-carriers (HPAH: 38.53 y ± 12.38 and IPAH: 45.78 y ± 11.32, p \< 0.01), respectively. Since the mutation carrier status could not be clarified in these families they have been excluded for the genotype-phenotype comparison (Figure [1](#F1){ref-type="fig"}). Gender distribution was slightly but not significantly different in the mutation carriers (female/male ratio 1.9:1) and non-carriers (ratio 3:1, table [1](#T1){ref-type="table"}).

###### 

Clinical characteristics at diagnosis

  --------------------------------------------------------------------------------------------------------------------------------
                                       *t-test*   n = 228\                                                               
                                                  43.49 y ± 12.75                                                        
  ------------------------------------ ---------- ----------------------- --------------------------- ------------------ ---------
  ***Patients***                                  **Mutation carrier**\   **Mutation non carrier**\                      
                                                  **n = 49**              **n = 179**                                    

                                                                                                                         

  *Age at onset (years)*               *\*\**     38.53 y ± 12.38         45.78 y ± 11.32                                

  *female/male (ratio)*                           32/17 (1.9:1)           134/45 (3:1)                                   

  *NYHA at diagnosis*                             III-IV                  II-IV                                          

                                                                                                                         

  *Pulmonary hemodynamic parameters*                                                                                     

                                                                                                                         

  *Heart rate per minute*              *\**       83.57 ± 11.79           n = 28                      77.38 ± 9.07       n = 88

                                                                                                                         

  *SaO^2^(%)*                                     92.85 ± 3.06            n = 26                      92.68 ± 3.29       n = 83

                                                                                                                         

  *PASP (mm Hg)*                       *\**       98.5 ± 16.35            n = 26                      87.73 ± 18.78      n = 83

                                                                                                                         

  *PADP (mm Hg)*                                  44.5 ± 7.5              n = 26                      36.37 ± 9.22       n = 81

                                                                                                                         

  *mPAP (mm Hg)*                       *\*\*\**   62.63 ± 9.92            n = 35                      53.44 ± 12.18      n = 135

                                                                                                                         

  *PCWP*                                          7.08 ± 3.16             n = 26                      7.75 ± 2.42        n = 83

                                                                                                                         

  *SASP (mm Hg)*                       *\**       118.11 ± 14.34          n = 27                      128.13 ± 18.59     n = 86

                                                                                                                         

  *SADP (mm Hg)*                                  76.5 ± 11.81            n = 27                      76.67 ± 10.60      n = 86

                                                                                                                         

  *CI (Litres/min/m^2^)*               *\*\*\**   1.67 ± 0.25             n = 31                      2.10 ± 0.53        n = 124

                                                                                                                         

  *PVRI*                               *\*\*\**   2306.53 ± 770.33        n = 25                      1503.25 ± 671.76   n = 116

                                                                                                                         

  *PVR*                                *\*\*\**   1519.65 ± 374.65        n = 22                      1000.36 ± 456.51   n = 71
  --------------------------------------------------------------------------------------------------------------------------------

\* \< 0.05

\*\* \< 0.01

\*\*\* \< 0.005

*BMPR2*mutation carriers had a significantly higher mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR), and a significantly lower cardiac index (CI) than non-carriers (Table [1](#T1){ref-type="table"}). Both groups did not significantly differ in WHO-functional class, oxygen saturation, heart rate, pulmonary capillary wedge pressures (PCWP), and systemic arterial systolic (SASP) and diastolic (SADP) blood pressures (Table [1](#T1){ref-type="table"}).

No correlation was seen in our data between truncating or missense mutation and sex, age of onset, and hemodynamic measurements (data not shown).

*BMPR2*mutations (Table [2](#T2){ref-type="table"})
---------------------------------------------------

###### 

Details of *BMPR2*mutations

  --------------------------------------------------------------------------------------------------------------------------
  Patient   new   Mutation\   Nucleotide Change       Amino Acid Change   Mutation type                   Age at diagnosis
                  Location\                                                                               
                  Exon                                                                                    
  --------- ----- ----------- ----------------------- ------------------- ------------------------------- ------------------
  K6628           1           c.?\_-540_76\_?del      Del aa1-25?         Deletion                        50 y

  K4808           1           c.?\_-540_76\_?del      Del aa1-25?         Deletion                        23 y

  K9063           1           c.48G \> A              p.W16X              Nonsense                        14 y

  K4518     \*    2           c.91G \> T              p.E31X              Nonsense                        45 y

  K4452     \*    2           c.244C \> T             p.Q82X              Nonsense                        39 y

  K1893     \*    2-3         Del c.77?-c.418?                            Deletion                        27 y

  K7369           3           c.353C \> T             p.C118Y             Missense                        56 y

  K15016          3           c.377A \> G             p.N126S             Missense                        28 y

  K14629          3           c.377A \> G             p.N126S             Missense                        61 y

  K7341           3           c.?\_248-c.418\_?del                        Deletion                        31 y

  K2878     \*    Intron 3    c.418+5G \> A                               Splice defect                   25 y

  K14983          4           c.439C \> T             p.R147X             Nonsense                        49 y

  K6834     \*    4           c.461C \> G             p.A154G             Missense/unclassified variant   33 y

  K7833           4           c.507 C \> A            p.C169X             Nonsense                        41 y

  K2917     \*    4-13        Del c.419? - c.3017?                        Deletion                        30 y

  K6565           6           c.631G \> A             p.R211X             Nonsense                        51 y

  K6686     \*    6           c.660insG               p\. G220fsX224      Frameshift                      18 y

  K14147          6           c.818T \> G             p.M273R             Missense                        59 y

  K5429           7           c.961C \> T             p.R321X             Nonsense                        27 y

  K5633           7           c.961C \> T             p.R321X             Nonsense                        50 y

  K12665          7           c.961C \> T             p.R321X             Nonsense                        69 y

  K3771           Intron 8    c.1128+1G \> T          del aa323-425       Splice defect                   40 y

  K7892     \*    9           c.1157A \> G            p.E386G             Missense/unclassified variant   52 y

  K8027           9           c.1259G \> A            p.C420Y             Missense                        56 y

  K11314          9           c.1258T \> C            p.C420R             Missense                        28 y

  K15582    \*    10          c.1296C \> G            p.Y432X             Nonsense                        28 y

  K15529          10          c.1297C \> T            p.Q433X             Nonsense                        32 y

  K4690           10          c.1313-1316delCAGA      p.T438fsX472        Frameshift                      43 y

  MHH09           10          c.1348C \> T            p.Q450X             Nonsense                        44 y

  MHH52           10          c.1388insA              p.P463fsX470        Frameshift                      52 y

  K5943           10          c.1397G \> A            p.W466X             Nonsense                        47 y

  K14763    \*    Intron 10   c.1413+1G \> A                              Splice defect                   43 y

  K7816           Intron 10   c.1413+3A \> T          p.G426fsX453        Splice defect                   45 y

  K12666    \*    11          c.1460A \> T            p.D487V             Missense/unclassified variant   42 y

  K6717           11          c.1471C \> T            p.R491W             Missense                        70 y

  K6361           11          c.1471C \> T            p.R491W             Missense                        40 y

  K6201           11          c.1471C \> T            p.R491W             Missense                        30 y

  K11744          11          c.1472G \> A            p.R491Q             Missense                        26 y

  K5590           11          c.1483C \> T            p.Q495X             Nonsense                        35 y

  K7936     \*    11          c.1523G \> A            p.W508X             Nonsense                        40 y

  K13356          11-12       Del c.1414-? \_2866+?                       Deletion                        17.25 y

  K10005    \*    12          c.1598A \> G            p.H533R             Missense                        26 y

  MHH18           12          c.1750C \> T            p.R584X             Nonsense                        62 y

  K14424    \*    12          c.2308delC              p.R770fsX771        Frameshift                      29 y

  K12298          12          c.2617C \> T            p.R873X             Nonsense                        50 y

  K12921          12          c.2617C \> T            p.R873X             Nonsense                        53 y

  K13213    \*    12          c.2626C \> T            p.Q876X             Nonsense                        26 y

  K8521           12          c.2695C \> T            p.R899X             Nonsense                        34 y

  K10327          12          c.2695C \> T            p.R899X             Nonsense                        19 y
  --------------------------------------------------------------------------------------------------------------------------

New identified mutations are indicated by asterisks (\*)

In 49 HPAH patients heterozygous alterations (46 mutations and 3 unclassified variants) in the *BMPR2*gene were identified; 12 mutations and 3 unclassified variants have been detected for the first time in this study (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). Table [2](#T2){ref-type="table"} lists all identified sequence alterations, the type of alteration, their location in the gene, and the age at diagnosis. New identified mutations or unclassified variants of the *BMPR2*gene are indicated by asterisks.

![**Location of the new identified sequence alterations (mutations and/or unclassified variants)**. The figure shows the location of all newly identified mutations/unclassified variants through the *BMPR2*transcript. Larger deletions are shown as line below the transcript, point mutations (nonsense and missense), splice site mutations and frameshift mutations are marked above the transcript as arrows, boxes represent exons, and colours of the boxes represent the different domains. Unclassified sequence alterations are highlighted in green and a dotted arrow. Mutations which are detected multiple times are only shown once. The mutations are widely distributed throughout the whole gene but two clusters are recognisable: cluster 1 lies in the extracellular domain (exons 2-4) whereas cluster 2 comprises exons 9 to 11 (serine/threonine protein kinase domain).](1465-9921-12-99-2){#F2}

### Distribution and frequency of BMPR2 mutations

The 49 *BMPR2*mutation types identified in the study population were: 35 point mutations (21 nonsense mutations and 14 missense mutations), 4 splice site mutations (all with affected splice donor sites), 4 frameshift mutations (small deletions/insertions) and 6 large deletions. The nonsense and the frameshift mutations resulted in a premature termination of the protein. The mutations were distributed throughout the whole *BMPR2*gene with two clusters in a) the extracellular domain (exons 2-4) and b) the serine/threonine protein kinase domain (exons 9-11). Four mutations occurred in more than one independent patient/family: p.R491W and p.R321X three times, respectively; p.C420Y, p.R873X and p.R899X two times, respectively.

In 8 of the 209 apparently sporadic cases *BMPR2*mutations have been identified and subsequently, thorough analysis of their family members revealed the same mutation in further asymptomatic members (in 3 parents, 5 children, 2 siblings), indicating that the proportion of sporadic PAH has been over estimated.

### New mutations (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"})

Five of the 12 identified, to the best of our knowledge not yet described *BMPR2*mutations were nonsense mutations, 2 frameshift mutations, 2 larger deletions, 2 splice defects, and one missense mutation. The *BMPR2*mutations have been identified in exon 2-3, 6, 10, 11, and 12 (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}).

Three of the identified 14 missense mutations are unclassified sequence variants (p.E386G, p.D487V and p.A154G) (Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Their disease causing potential has not been clearly verified. Analysis of these variants by use of the program MutationTaster \[[@B20]\] showed that all three variants are predicted to be most likely disease causing mutations (Table [3](#T3){ref-type="table"}). The p.E386G and the p.D487V variants were both located in the serine/threonine kinase domain which is a highly conserved region among different species and suggests an important role in the function and/or structure of this region whereas the p.A154G variant was located at the beginning of the transmembrane domain. The variants were additionally analysed with the program ESEfinder \[[@B21],[@B22]\] to investigate whether these substitutions might have an effect on exonic splicing. According to this analysis, the p.A154G and p.D487V variants had no effect on ESE binding sites whereas the p.E386G variant resulted in loss of 1 SF2/ASF- and 1 SRp40-site, respectively which might have an influence on the correct splicing \[Table [3](#T3){ref-type="table"}\].

###### 

Analysis of the Unclassified *BMPR2*Sequence Variants by use of computer prediction programs

  Unclassified variant   Localization                     MutationTaster prediction   Conservation across different species   ESEfinder prediction            Clinical classification according to family history
  ---------------------- -------------------------------- --------------------------- --------------------------------------- ------------------------------- -----------------------------------------------------
  p.A154G                Transmembrane domain             Disease causing             conserved                               Not affected                    IPAH
                                                                                                                                                              
  p.E386G                Serine/threonine kinase domain   Disease causing             conserved                               SF2/ASF-& SRp40-site affected   IPAH
                                                                                                                                                              
  p.D487V                Serine/threonine kinase domain   Disease causing             conserved                               Not affected                    PAH with familial history

Clinical characterization of patients with familial PAH but no detectable mutation
----------------------------------------------------------------------------------

Only in 3 out of the 22 families with HPAH (13.6%, Figure [3](#F3){ref-type="fig"}) examination of the *BMPR2*gene (promoter and coding regions including flanking intronic regions) and the coding regions of the *ACVRL1*, *ENDOGLIN*, and the *SMAD8*genes did not reveal any defect. Especially, no point mutations or gross deletions/duplications were detectable.

![**Pedigree trees of familial PAH cases without mutation**. The figure represents pedigree trees of familial cases without mutation in *BMPR2*, *ACVRL1*, *ENG*, and *SMAD8*(family S1490; family S1644 and family K8139). The index patient of each family is marked by an arrow. The father of the index patients in family S1644 also died quite young with an age of 47 due to an accident.](1465-9921-12-99-3){#F3}

In the affected members of all three families PAH has been diagnosed very early (mean age: 27.3 y ± 4.78) and was characterised by a very severe and rapid progressive clinical phenotype (mean hemodynamic values of the index patients catheterization at diagnosis were: mPAP: 56.3 ± 13.22 mmHg; PCWP: 7.7 ± 2.05 mmHg; CI: 2.01 ± 0.47; mean PVR 812 ± 68 dyn; heart rate 91.7 ± 9.43 beats/min). Although no mutations could be identified in the coding regions of the investigated genes there might be defects located in deeper intronic regions which could not be detected by conventional analysis methods or in other, until now, not identified genes participating in the *BMPR2*signalling pathway.

Family S1490
------------

The male index patient (II:4) in this family presented first symptoms at age of 31 years and died early at an age of 33 years due to sudden right heart failure after an infection, two months after PAH was diagnosed. About 20 years later his children presented for familial screening assessment in Heidelberg. This analysis revealed a severe PAH in his two daughters (III:2, III:3). They have been early listed for double lung transplantation, which has been successfully performed 2 years after diagnosis.

Family S1644
------------

The female index patient (III:1) of this family was invasively diagnosed at an age of 22 years. She was severely affected with NYHA class III, severely impaired right ventricular function and hemodynamic values (heart rate per min: 85; mPAP: 75 mmHg; PCWP: 8 mmHg; CI: 2.0). Her sister (III:2) died very young (age 22 years) because of PAH, no DNA sample was available. She had dyspnoea from early childhood on and was initially diagnosed as bronchial asthma although no asthma attacks had occurred. The father also died quite young with an age of 47 years because of an accident and could not be examined. No other family members showed signs of PAH. Sequence and MLPA analysis were both negative for mutations or deletion/duplication in all investigated genes (Figure [3](#F3){ref-type="fig"}).

K8139A
------

A rapid progressive clinical phenotype has been detected in this family as well. The male index patient (II:2) showed first symptoms of PAH at an age of 33 years which was finally confirmed by right heart catheterization at age of 34 years (heart rate per min: 105; pulmonary arterial systolic pressure: 68 mmHg; pulmonary arterial diastolic pressure: 36 mmHg; mPAP: 46 mmHg; PCWP: 5 mmHg; SASP: 85 mmHg; SADP: 60 mmHg; CI: 1.44; PVR: 744 dyn). He presented with NYHA class III-IV, severely impaired right ventricular function and died finally at the age of 38 years although he has received a triple PH-specific therapy including intravenous prostacyclin. He had refused the listing for lung transplantation. His affected older brother (II:1) died also very young (age 26 years) because of PAH within three months after appearance of the first symptoms. No DNA sample was available from him. The father (I:1) died at age of 68 years due to an apoplexy. The familial screening assessment revealed no PAH in any other family member so far (Figure [3](#F3){ref-type="fig"}).

Discussion
==========

In this study, we confirmed previous findings that *BMPR2*mutation carriers are younger at diagnosis with a more severe hemodynamic compromise in a large prospectively assessed cohort of patients with confirmed PAH. Furthermore, we identified 12 to the best of our knowledge not yet described *BMPR2*mutations and 3 unclassified sequence variants.

The study obtained *BMPR2*mutations in 86.4% of HPAH patients with a positive family history and in 14.4% of patients with apparently sporadic disease. Only in 3 out of 22 families with confirmed HPAH (13.6%) no genetic defect could be detected. This result suggests that with the increasing knowledge on *BMPR2*sequence alterations and the improving diagnostic genetic techniques the rate of identifiable genetic defects in familial PAH might be even higher ( \> 80%) than previously suggested (≈ 70%) \[[@B1],[@B7]\].

BMPR2 mutations and clinical phenotype
--------------------------------------

Previous data indicated that having *BMPR2*mutations is associated with a more aggressive form of PAH based on an earlier age at diagnosis and more severe hemodynamic \[[@B6],[@B12]-[@B15]\]. Although survival was similar in mutation carriers and non-carriers, patients with *BMPR2*mutation were more likely to be treated with parenteral prostacyclin therapy or to undergo lung transplantation \[[@B13]\]. Worse hemodynamic parameters \[[@B12]\] and reduced vasoreactivity \[[@B6],[@B12],[@B14]-[@B16]\] have been described in PAH-patients with non-synonymous *BMPR2*mutations. The study performed by Rosenzweig et al \[[@B12]\] included children and showed a significant lower cardiac index but no significantly higher mPAP or PVR. No significantly differences in the hemodynamic parameters of mutation carriers vs. non-carriers have been found by Dewachter et al \[[@B23]\]. They suggested this might be due to the small number of patients (n = 28) in this study \[[@B23]\].

However, some studies have been retrospective in design. Our study has analysed the impact of *BMPR2*mutations on the age at diagnosis and hemodynamic parameters for the first time in a prospective design and confirms the findings of the previous studies \[[@B6],[@B12],[@B14],[@B15]\].

Due to the limited number of patients carrying a *BMPR2*mutation most studies do not allow to sufficiently correlate distinct mutation types with clinical presentation. Austin et al. \[[@B17]\] showed that PAH patients carrying a truncating mutation in the *BMPR2*gene developed a more severe disease than patients without truncating mutation. No correlation was seen in our data between truncating mutation and gender, age of onset, and hemodynamic values. This is in concordance with the results of the French PAH registry \[[@B15]\].

Since occurrence of *BMPR2*mutations obviously influences the clinical phenotype genetic testing may become of increasing clinical relevance. Patients with *BMPR2*mutation tend to a more severe clinical phenotype and might be followed more closely. Clinical assessment of family members \[[@B11],[@B24]\] might be therefore especially of importance in patients with detected mutations.

Identification of new *BMPR2*mutations
--------------------------------------

In this study we identified different types of mutations resulting in a truncated protein which might all interfere with the downstream signalling of the BMP pathway (for example by nonsense mediated decay) and activate proliferating pathways \[[@B25]\]. The detected *BMPR2*mutations were distributed throughout the whole gene with 2 clusters as described previously \[[@B1],[@B6],[@B15]\]. Cluster 1 was located in the extracellular domain (exons 2-4) whereas cluster 2 comprised exons 9 to 11 (serine/threonine protein kinase domain). As a consequence the complete gene should be genetically analysed in clinical routine.

From 49 mutations 12 were newly identified and were predominantly nonsense mutations. Three newly found missense mutations were termed unclassified variants because their disease causing potential has not been clearly verified until now. Analysis of these variants by usage of different prediction programs showed that all three variants are predicted to be most likely disease causing mutations (Table [3](#T3){ref-type="table"}). Two of them (p.E386G and p.D487V) are located in the serine/threonine kinase domain which is a highly conserved region among different species and suggests an important role in the function and/or structure of this region whereas the third (p.A154G) variant is located at the beginning of the transmembrane domain. Therefore, all three variants are predicted to have an impact on the proper function of the protein.

PAH families without *BMPR2*mutation
------------------------------------

Three of the 22 familial PAH cases without mutation in the *BMPR2*gene investigated in our study did not reveal defects of the *ACVRL1*gene, the *ENG*gene, and the *SMAD8*gene. We have excluded them from genotype-phenotype analysis to reduce the risk of misclassification as has been described before \[[@B15]\]. Interestingly, mean age at diagnosis in this small group was even significantly lower as in all other patients. Girerd and collegues \[[@B14]\] described this for patients with familial PAH and hereditary hemorrhagic telangiectasia carrying a mutation in the *ACVRL1*gene. In our families hereditary hemorrhagic telangiectasia and *ACVRL1*gene defects have been excluded. The proportion of patients with familial aggregation but no detectable *BMPR2*mutation was in our study even lower (13.6%) than in other cohorts (17.6% in the study performed by Austin et al. and 26.3% in the French registry, respectively \[[@B6],[@B17]\]). Consequently, it may be assumed that mutations in the known genes *BMPR2*, *Activin A receptor type II-like 1, Endoglin*, and *SMAD8*are not the only cause of the disease. However, in our 3 *BMPR2*negative PAH families it is alternatively possible that these patients carry mutations in intronic or regulatory regions, which have not been detected by the used standard techniques.

Thus, in patients with familial aggregation of PAH *BMPR2*mutations are most likely. Genetic testing including the complete *BMPR2*gene may improve risk stratification in all patients with PAH.
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